ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1504

A Possible Contribution of Visfatin to the Resolution of Skin Sclerosis in Patients with Diffuse Cutaneous Systemic Sclerosis Via a Direct Anti-Fibrotic Effect On Dermal Fibroblasts and Th1 Polarization of the Immune Response

Tetsuo Toyama1, Yoshihide Asano2, Yuri Masui3, Sayaka Shibata2, Kaname Akamata1, Shinji Noda2, Naohiko Aozasa1, Takashi Taniguchi2, Takehiro Takahashi2, Yohei Ichimura2, Hayakazu Sumida2, Koichi Yanaba2, Takafumi Kadono2 and Shinichi Sato1, 1Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, 2Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, 3Department of Dermatology, University of Tokyo, Tokyo, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Adipocytokines and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s – Pathogenesis, Animal Models and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Our latest studies have demonstrated that adipocytokines, including adiponectin, apelin, and retinol-binding protein-4, are potentially involved in the development of complicated clinical symptoms associated with systemic sclerosis (SSc). Visfatin is another member of adipocytokines with pro-fibrotic, pro-inflammatory, and immunomodulating properties, having been implicated in the pathogenesis of certain fibrotic and inflammatory autoimmune diseases. As an initial step of a series of studies regarding the role of vistatin in the pathogenesis of SSc, we herein investigated the clinical significance of serum visfatin levels and its contribution to the developmental process in this disorder.

Methods: Serum visfatin levels were determined by a specific ELISA in 57 SSc patients and 19 healthy controls. The effects of visfatin on the mRNA levels of a2(I) collagen (COL1A2) and matrix metalloproteinase-1 (MMP-1) genes were examined in normal and SSc dermal fibroblasts by reverse-transcript real-time PCR. The levels of IL-12p70 produced by THP-1 cells differentiated with IFN-g plus LPS in the presence or absence of visfatin were measured by a specific ELISA.

Results: Serum visfatin levels were comparable among total SSc, diffuse cutaneous SSc, limited cutaneous SSc, and healthy controls. The only finding in a series of analyses regarding the correlation of serum visfatin levels with clinical symptoms and laboratory data was the significantly longer disease duration in dcSSc with elevated serum visfatin levels than in those with normal levels. Consistently, serum visfatin levels were significantly elevated in late stage dcSSc (disease duration of > 6 years), but not in early and mid-stage dcSSc, compared with healthy controls, suggesting the possible contribution of visfatin to the resolution of skin sclerosis in late stage dcSSc. To assess this hypothesis, two sets of in vitro experiments were carried out using dermal fibroblasts and THP-1 cells. Visfatin suppressed the mRNA levels of COL1A2 gene, while increasing the mRNA levels of MMP-1 gene, in a dose-dependent manner in SSc dermal fibroblasts, whereas the mRNA levels of these genes were not affected by visfatin at all in normal dermal fibroblasts, indicating the direct anti-fibrotic effect of visfatin on SSc dermal fibroblasts. Furthermore, visfatin increased the production of IL-12p70 in THP-1 cells differentiated with IFN-g plus LPS in a dose-dependent manner, suggesting the promotion of Th1 immune responses by visfatin.

Conclusion: Visfatin may contribute to the resolution of skin sclerosis in late stage dcSSc via the direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response.


Disclosure:

T. Toyama,
None;

Y. Asano,
None;

Y. Masui,
None;

S. Shibata,
None;

K. Akamata,
None;

S. Noda,
None;

N. Aozasa,
None;

T. Taniguchi,
None;

T. Takahashi,
None;

Y. Ichimura,
None;

H. Sumida,
None;

K. Yanaba,
None;

T. Kadono,
None;

S. Sato,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-possible-contribution-of-visfatin-to-the-resolution-of-skin-sclerosis-in-patients-with-diffuse-cutaneous-systemic-sclerosis-via-a-direct-anti-fibrotic-effect-on-dermal-fibroblasts-and-th1-polarizati/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology